Sinew Pharma Inc. (6634.TWO)
Taipei Exchange · TWD · Healthcare · Biotechnology
NT$57.00 (+2.89%) as of
Key statistics
- Market cap
- 4.06B
- EPS (TTM)
- -1.66
- Dividend yield
- 0.00%
- 52-week range
- 29.05 – 85.00
- Beta
- 0.56
- Revenue (TTM)
- 47k
- Profit margin
- 0.00%
- Volume
- 69.53k
About Sinew Pharma Inc.
Sinew Pharma Inc., a biopharmaceutical company, focuses on the research, development, and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company's products include SNP-610 drug, which is in Phase IIa clinical trial and SNP-630 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan. It is also developing SNP-810 is in phase II clinical trial for use in pain relief and fever reduction; SNP-820 is in Phase II clinical trial for antidote for acetaminophen poisoning, and SNP-830 and SNP-840, which in pre-clinical trial are used as hepatotoxicity-free analgesic medicines in the United States. Sinew Pharma Inc. was founded in 2014 and is based in Taipei City, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Taipei, Taiwan
- Employees
- 52
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.